Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N-methyl amisulpride - LB pharmaceuticals

Next Previous
Drug Profile

N-methyl amisulpride - LB pharmaceuticals

Alternative Names: LB 102; LB 102 LAI; LB-102 - LB Pharmaceuticals

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LB Pharmaceuticals
  • Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 26 Sep 2025 Phase II development is ongoing in USA
  • 31 Mar 2025 LB Pharmaceuticals plans clinical trials in Bipolar depression, Schizophrenia, Alzheimer’s disease and other psychiatric indications
  • 31 Mar 2025 Updated efficacy and adverse events data from the phase II NOVA trial in Schizophrenia released by LB Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top